Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

936.00 -22.91 (-2.39%)
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 302,245
Open 957.22
Bid (Size) 935.90 (120)
Ask (Size) 936.47 (40)
Prev. Close 958.91
Today's Range 935.24 - 972.38
52wk Range 661.85 - 1,072.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
From argenx SE
Via GlobeNewswire
News headline image
Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months ↗
There are good reasons behind analyst's bullish views of this biotech stock. 
Via The Motley Fool

Performance

YTD
+11.4%
+11.4%
1 Month
-9.3%
-9.3%
3 Month
+2.9%
+2.9%
6 Month
+26.0%
+26.0%
1 Year
+26.9%
+26.9%

More News

Read More
News headline image
2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right. ↗
Via The Motley Fool
News headline image
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
From argenx SE
Via GlobeNewswire
ARGENX SE - ADR (NASDAQ:ARGX) Meets Minervini Trend Template and High Growth Momentum ↗
Via Chartmill
News headline image
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? ↗
Via The Motley Fool
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
argenx Completes Acquisition of Forte Biosciences, Inc.
From argenx SE
Via GlobeNewswire
News headline image
Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story ↗
Via The Motley Fool
News headline image
Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Via Benzinga
News headline image
These Analysts Boost Their Forecasts On Argenx ↗
Via Benzinga
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing ↗
Via MarketBeat
Topics Intellectual Property
News headline image
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
From argenx SE
Via GlobeNewswire
News headline image
Here’s How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
Via Benzinga
News headline image
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
From argenx SE
Via GlobeNewswire
News headline image
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102 ↗
Via MarketBeat
Topics Intellectual Property
News headline image
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
From Forte Biosciences, Inc.
Via Business Wire
News headline image
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
From argenx SE
Via GlobeNewswire
News headline image
argenex Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings Intellectual Property
News headline image
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
From argenx SE
Via GlobeNewswire

Frequently Asked Questions

Is argenx SE - American Depositary Shares publicly traded?
Yes, argenx SE - American Depositary Shares is publicly traded.
What exchange does argenx SE - American Depositary Shares trade on?
argenx SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for argenx SE - American Depositary Shares?
The ticker symbol for argenx SE - American Depositary Shares is ARGX on the Nasdaq Stock Market
What is the current price of argenx SE - American Depositary Shares?
The current price of argenx SE - American Depositary Shares is 936.00
When was argenx SE - American Depositary Shares last traded?
The last trade of argenx SE - American Depositary Shares was at 10/01/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.